Hemab Therapeutics Earnings
NASDAQ: COAGHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
31.62+0.73 (+2.36%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Hemab Therapeutics earnings summary
In its most recent report on Aug 11, 2026 (Q2 2026), COAG posted EPS of $-0.80.
Summary generated from market data by MetaCap's automated system. Methodology
COAG earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 11, 2026 | — | $-0.80 | — | -10.5% |
| May 21, 2026 | — | $-23.98 | — | +10.1% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.